Cat. No. 1225
Chemical Name: 1,4-Bis(3,5-Dichloro-2-pyridinyloxy
Biological ActivityAgonist of the constitutive androstane receptor (CAR) (EC50 = 20 nM). Induces activity of ER1 cytochrome P450 isozymes, NADPH-cytochrome c reductase, microsomal epoxide hydrolase and glutathione S transferase. Potent mitogen; induces liver cell proliferation in mice.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Tzameli et al (2000) The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol.Cell.Biol. 20 2951. PMID: 10757780.
Ledda-Columbano et al (1998) In vivo hepatocyte proliferation is inducible through a TNF and IL-6-independent pathway. Oncogene 17 1039. PMID: 9747883.
Poland et al (1980) 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene, a potent phenobarbital-like inducer of microsomal monooxygenase activity. Mol.Pharmacol. 18 571. PMID: 7464820.
If you know of a relevant reference for TCPOBOP please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses TCPOBOP from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: TCPOBOP, supplier, agonists, nuclear, receptor, CAR, constitutive, androstane, receptors, mitogens, mitogenic, Tocris Bioscience, Constitutive Androstane Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Synthetic progesterone analogC-DIM 12
Nurr1 activator; inhibits NF-κB-dependent gene expression(S)-Equol
Potent estrogen receptor β (ERβ) agonistAilanthone
Potent inhibitor of androgen receptor (AR)(±)-ML 209
RORγt inverse agonist; suppresses Th17 cell differentiationAGN 193109
High affinity pan-RAR antagonistSR 9243
Selective LXR inverse agonist
August 20 - 24, 2017
Paris , France